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from approximately 2.5 million patients. Data was extracted for insulin naïve and 
prior insulin T2D patients initiated on basal insulin as monotherapy or as part of a 
basal-bolus regimen in 2004–2006. RESULTS: The study included 7209 new basal 
insulin users, of which 4792 (67%) were insulin naive. Overall, 4728 (66%) used 
analogues, with similar proportions using monotherapy (67%) and basal-bolus 
therapy (65%). The proportion of analogue users was greater among prior insulin 
users: 541 of 619 (87%) for monotherapy and 1331 of 1798 (74%) for basal-bolus 
therapy compared with 2258 of 3702 (61%) and 598 of 1090 (55%) among naïve 
users. Monotherapy for naïve patients was initiated mainly by the GP (NPH 70%, 
analogue 59%), for prior users mainly by the internist (NPH 49%, analogue 59%)%), 
same as for basal-bolus users (NPH 67–68%, analogue 75–80%). With NPH, 22% 
discontinued their prescription (average of 220 days) and with basal analogues 17% 
(average of 230 days). Furthermore, 6% of patients on NPH and 11% with basal 
analogues added-on to their prescription (after an average of 119 days and 126 days, 
respectively). Only 17% of patients switched treatment with basal analogues com-
pared with NPH (average of 190 days) versus 32% (average of 158 days), respectively. 
CONCLUSIONS: When new insulin treatment is initiated, analogues are more often 
prescribed than NPH, more frequently prescribed by Dutch internists and not discon-
tinued or switched as frequently as NPH, indicating that basal insulin analogues give 
a more sustained and satisfactory result.
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OBJECTIVES: Many aspects of the scientiﬁc, economic and political discussions on 
the beneﬁt of new medicines, for which modern insulins are a pivotal example, inﬂu-
ence recent decisions about drug reimbursement. This study was undertaken to 
compare the reimbursement status of long acting insulin analogues (LAIA) in several 
industrialized countries around the globe, where different criteria for public funding 
of pharmaceuticals have been used, but all include estimates of clinical effectiveness 
and/or cost effectiveness. METHODS: The study was performed based on a combina-
tion of desk research, direct contact with national diabetes stakeholders and expert 
review, using a pre-deﬁned questionnaire. In the ﬁrst phase, information was gathered 
from each country on diabetes prevalence, cost, relevant policies and guidelines through 
a range of sources including government and patient association websites, published 
scientiﬁc literature, media reports. In the second phase additional information about 
reimbursement status of LAIA was sought from recommendations obtained from the 
websites of HTA or similar agencies, or interviews carried out with national stakehold-
ers representing health ministries, patient organisations or medical community. 
RESULTS: Fifteen countries have been included in the study (Australia, New Zealand, 
Canada, UK, The Netherlands, France, Germany, Austria, Sweden, Norway, Latvia. 
Lithuania, Estonia, Hungary, Bulgaria). Only in France LAIA are reimbursed in 65%, 
in all remained countries—in 100%. But in most countries there are several restrictions 
on access to LAIA, namely criteria for this type of treatment have been developed to 
respond the clinical and economic evidence (use in selected patients, application only 
from a relevant specialist, regular reassessments of metabolic control, listing after the 
company agreed to a price reduction). CONCLUSIONS: The story of LAIA is impor-
tant not only because of the way the evidence has been interpreted, but because the 
voice of consultative bodies resulted in action by the health care purchasers.
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HEALTH CARE UTILISATION AND EXPENDITURES ASSOCIATED WITH 
TREATMENTS OF DIABETES MELLITUS WITHIN THE SLOVAK 
REPUBLIC
Tesar T, Foltan V, Binder R
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OBJECTIVES: The aim of this study was to collect comparable and reliable data about 
consumption of drugs for treatment of diabetes mellitus in Slovakia during the period 
1999–2008. METHODS: Data of wholesalers (following ATC/DDD), who are legally 
obliged provide this information to the Slovak Institute for Drug Control, was used 
for the analysis. The results were expressed in the numbers of the packages, ﬁnance 
units (a) and deﬁned daily doses per 1000 inhabitants per day (DID). RESULTS: The 
collected data shows a signiﬁcant increases in the antidiabetic’s consumption from 
1999 to 2008 in term of DID (in 1999 (33.34) and in 2008 (48.63)). A moderate 
increase in A10AB group (Insulins and analogues, fast-acting) in 1999 (3.03), in 2003 
(3.47) and in 2008 (5.25), a signiﬁcant decrease in A10AC group (Insulins and ana-
logues, intermediate-acting) in 1999 (4.79), in 2003 (3.94) and in 2008 (2.20), a 
moderate increase in A10AD (Insulins and analogues, intermediate-acting combin.) in 
1999 (2.47), in 2003 (2.71) and in 2008 (4.05), a noticeable increase in A10AE 
(Insulins and analogues, long-acting) in 1999 (0.05), in 2003 (0.02) and in 2008 
(1.99), a dramatic increase in A10BA (Biguanides) in 1999 (4.82), in 2003 (7.66) and 
in 2008 (13.51), a relatively stable consumption in A10BB (Sulfonamides) in 1999 
(17.57), in 2003 (15.87) and in 2008 (19.29) and a moderate increase in A10BD 
(Biguanides and sulfonamides in combination) in 1999 (0.52), in 2003 (0.95) and in 
2008 (1.68) in term of DID can be seen from this analysis. Financial expenditures for 
antidiabetics were in 1999 (a19,271,000) and in 2008 (a38,952,000). CONCLU-
SIONS: Inseparable components of the Slovak drug policy must be viewed realistically 
with regard to the antidiabetics’ consumption. Adherence to principles of diabetes 
mellitus treatment’s guidelines lead to fundamental short and long term ﬁnancial 
savings within health care systems.
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OBJECTIVES: Exenatide and glargine are used for the treatment of type 2 diabetes 
(T2D) patients who are inadequately controlled on oral antidiabetic (OAD) medica-
tions. This study examined concomitant medications (including “off- label” use), 
resource utilization, and mean HbA1C (A1C) reduction after initiation of exenatide 
compared to glargine. METHODS: A retrospective claims analysis comprised of adult 
patients with T2D who initiated exenatide (N  9264) or glargine (N  3791) therapy 
between April 1, 2005 and June 30, 2007. Concomitant medications and resource 
utilization were estimated using logistic regression with propensity score stratiﬁcation 
used to control for baseline patient characteristics. A subgroup analysis was performed 
in patients who had baseline and follow-up A1C data for exenatide (n  606) and 
glargine (n  251) to examine mean A1C reduction. RESULTS: A higher percentage 
of exenatide-treated patients were using concomitant metformin only (21.4% vs. 
10.7%, p  0.0001) and a lower percentage were using concomitant sulfonylurea only 
(3.2% vs. 6.4%, p  0.001). There was no signiﬁcant differences between percentage 
of patients using at least 1 OAD medication (89.2% vs. 88.9%, p  0.14) in both 
cohorts. Exenatide-treated patients had 26% lower risk of hospitalizations (OR: 0.74, 
p  0.0001) mainly due to 38% lower risk of macrovascular complications (OR: 0.62, 
p  0.001). Exenatide-treated patients also experienced 22% lower risk of hypoglyce-
mic events (OR: 0.78, p  0.037). A higher percentage of exenatide-treated patients 
with a baseline A1C q 7% achieved an A1C goal of  7 (36.3% vs. 19.3%, p  0.001). 
Exenatide-treated patients experienced a signiﬁcantly greater mean reduction in A1C 
compared to glargine-treated patients after adjusting for baseline A1C (0.80 vs. 
0.52, p  0.0142). CONCLUSIONS: Most patients were concomitantly using some 
OAD medications in both cohorts. Exenatide-treated patients had a signiﬁcantly lower 
risk of hospitalizations, macrovascular complications and hypoglycemic events. In the 
patient subset with A1C data, exenatide-treated patients had a signiﬁcantly greater 
reduction in mean A1C and higher percentage achieving goal than glargine-treated 
patients.
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OBJECTIVES: Clinical evidence evaluating polypharmacy and health care utilization 
with the use of continuous subcutaneous insulin infusion (CSII) in persons with 
uncontrolled Type 2 diabetes is limited. This study provides a real-world (retrospec-
tive) evaluation of the impact of CSII among 973 patients with Type 2 diabetes initiat-
ing CSII therapy between January 2005–October 2007 (mean age 48 years, 47% male, 
mean duration of follow-up 17 months). We hypothesized that CSII therapy would 
reduce rates of polypharmacy (multiple diabetes medication use), ER visits, and hos-
pitalizations. METHODS: Administrative claims from a large, geographically diverse, 
US health plan were used. RESULTS: More than 1/3 of subjects taking oral anti-dia-
betic medications (OADs) before CSII initiation discontinued oral therapy altogether 
once they began CSII. The mean number of OADs used by subjects decreased by 0.67 
OADs (1.45 OADs before vs. 0.78 OADs after, p  0.001) after CSII initiation. The 
number of subjects using multiple OADs decreased by 58% (40% before vs. 17% 
after, p  0.001) and rates of switching or augmenting oral therapy decreased from 
44% to 25% (p  0.001) from baseline to follow-up. The rate of ambulatory visits 
increased from pre- to post-CSII initiation (1.80 visits/subject/month before vs. 2.01 
visits/subject/month after CSII initiation, p  0.01), likely reﬂecting increased use of 
diabetes education services related to CSII. However, the rates of ER visits (0.11 
visits/subject/month before vs. 0.08 visits/subject/month after, p  0.01) and hospital-
izations (0.03 visits/subject/month before vs. 0.01 visits/subject/month after, p  0.01) 
signiﬁcantly decreased after CSII initiation. CONCLUSIONS: Insulin pump therapy 
(CSII) was associated with signiﬁcant decreases in polypharmacy and medication 
changes. Also, CSII may lead to a reduction in health care utilization as indicated by 
reductions in rates of ER visits and hospitalizations.
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Diabetes is one of the most prevalent diseases of 21st century. In Greece, according to 
IDF, 737.700 people were suffering from diabetes in 2006 with prevalence rate 8.6% 
of the adult population. The Greek NHS decides reimbursement level based on disease. 
Nevertheless a paradox that exists in Diabetes case is that insulins are fully reimbursed 
whereas oral medications are reimbursed 75%. Moreover, the blood glucose measur-
ing tapes are distributed for free in patients taking insulin, contrary to patients in 
oral medications that have to pay the whole amount. OBJECTIVES: To assess the 
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preference of physicians in prescribing Oral Antidiabetic Treatments (OATs) versus 
Insulin in Diabetes patients. METHODS: A survey was conducted by CSD, face to 
face interviews with 200 physicians of several specialties, GPs, diabetologists, endo-
crinologists who treat at least 30 diabetic patients/month. The sample emerged from 
four capital cities of Greece. The sampling method was based on stratiﬁed random 
sample. Interviews were conducted from May 12 to June 3, 2009. Results were 
weighted according to the actual distribution of specialties. RESULTS: The number 
of patients with type-1 diabetes is approximately 12% and 88% with type-1 diabetes. 
In DT1 100% patients receive insulin, contrary to DT2 where patients receive 23% 
insulin and 83% OATs. Overall, 60% of T2D patients are regulated. Also when 
adding a third OAT drug 54% of the patients will delay the use of insulin. Unmet 
needs mentioned spontaneously by physicians are: a) poor compliance to treatment; 
b) poor compliance to diet; and c) high cost of co-payment for medicines. CONCLU-
SIONS: Based on the results of the present study, physicians use insulins for DTI 
patients and they prefer OATs for TIID. The economic burden of TIID patients is 
heavy due to high co-payment rate, which might be linked to poorly regulated patients 
leading to higher incidence of diabetes-related complications.
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OBJECTIVES: The specialist outpatient clinics (SOCs) of the 3 acute hospitals of the 
National Healthcare Group (NHG) in Singapore treat over 11,000 patients with dia-
betes mellitus. This paper studies the glycaemic and cholesterol control of type 2 dia-
betes mellitus (T2DM) patients at these SOCs. METHODS: This study included all 
patients with T2DM who attended the hospital SOCs in Jan 2009 for treatment of 
diabetes. These patients had been on follow-up at the same clinic for at least 12 months. 
The latest glycated haemoglobin (HbA1c) and LDL-cholesterol (LDL-c) results were 
compared by age, gender and ethnic group. Data was extracted from the NHG Diabetes 
Registry (CDMS). RESULTS: There were 3,420 T2DM patients with more females 
(53%) and disproportionately more Indians (14.1%) and fewer Chinese (66.3%) than 
the general population. The mean ages of male and female were 61.8 and 64.9 years 
respectively. The proportion of patients with “optimal” HbA1c (a7%) and LDL-c 
(2.6 mmol/L) control increased with age. For HbA1c, 13% of patients 35 years had 
“optimal” control (mean 8.96%, 95%CI 8.42–9.50%) increasing to 61% for patients 
85 years (mean 7.04%, 95%CI 6.79–7.28%). Similarly for LDL-c, 41% of patients 
35 years had “optimal” control (mean 2.92 mmol/L, 95%CI 2.63–3.21 mmol/L), 
increasing to 74% for patients 85 years (mean 2.28 mmol/L, 95%CI 2.14–2.41 mmol/L). 
Chinese had better HbA1c and LDL-c control whilst Malay and Indian were poorest 
for LDL-c and HbA1c respectively. There was no gender difference. CONCLUSIONS: 
The control of HbA1c and LDL-c among T2DM patients improved with age. Younger 
patients and the Malay and Indian subgroups had greater potential to achieve 
“optimal” glycaemic and cholesterol control and reduce the risk of developing 
micro- and macro-vascular complications over time. While the older patients achieved 
better HbA1c control than younger ones, clinicians should remain mindful of side-
effects such as hypoglycaemia among those with very tight glycaemic control.
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OBJECTIVES: This study was conducted to estimate quality adjusted life years 
(QALYs) loss due to diabetes in type 2 diabetic patients of South Korea. METHODS: 
In order to obtain QALYs loss due to morbidity of type 2 diabetes (T2D), we ﬁrstly 
estimated utility weight difference between T2D patients and non-diabetic subjects by 
sex and age groups. We consecutively recruited T2D patients aged 20 or over who 
visited three university hospitals in Seoul and Ilsan from October 2007 to January 
2008 and non-diabetic subjects who took a medical examination from June 2008 to 
Jan 2009 in same hospitals. Utility weight differences on sex and age groups were 
calculated using the EuroQoL EQ-5D and Korean valuation set, and then QALY losses 
was estimated using the utilities and the number of T2D patients in 2003 reported by 
the Korean Diabetes Basic Statistics Study. QALY losses due to T2D mortality corre-
sponded to life expectancy of the death caused T2D from the life table and the Korean 
Death Certiﬁcate in 2003 multiplied by utility weights of healthy people by sex and 
age groups from the 3rd Korea National Health and Nutrition Examination Survey 
(2005). We considered a discount rate as 5%. RESULTS: Total 1,072 T2D patients 
and 387 non-diabetic subjects participated in this survey. Maximum difference 
between T2D patients and non-diabetic subjects was 0.0418 and minimum difference 
was 0.0095 by subgroups. QALY loss estimates due to T2D morbidity were about 
35,125 QALYs in male and 50,613 QALYs in female. Preterm death caused by T2D 
brought about 58,186 QALYs in male and 49,432 QALYs in female considering the 
discount rate. Therefore, total QALY loss was estimated as 193,356 QALYs annually. 
CONCLUSIONS: The results suggest that QALY loss estimates caused by T2D was 
4.0 QALYs/1000 persons in South Korea at 2003.
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OBJECTIVES: To map factors that inﬂuence HTA-agencies in their Health Technol-
ogy Assessments (HTA) on type 2-diabetes agents in the UK (NICE), Scotland (SMC), 
The Netherlands (CVZ) Germany (IQWIG) and Sweden (TLV). METHODS: To 
retrieve the HTA reports, a search was executed using the agencies websites with the 
following keywords: pioglitazone, rosiglitazone, sitagliptin, vildagliptin, exenatide, 
glargine, detemir, aspart, glulisine and lispro. If a report contained several drugs each 
drug was counted separately although a decision could involve a class of drugs. Deci-
sion parameters were clustered in three categories: efﬁcacy, safety and health econom-
ics where each assessment could contain multiple parameters. Overall recommendation 
was classiﬁed in three categories: recommended restricted recommended and not 
recommended in relation to indication based on marketing authorisation. RESULTS: 
35 reports were identiﬁed with 49 assessments. Twelve assessments lead to recom-
mendation (24%), 23 to restricted recommendation (47%) and fourteen to no recom-
mendation (29%). Reasons for recommending a treatment contained in 83% of cases 
one or more arguments related to efﬁcacy, 33% to safety, and 66% to health economic 
aspects of drugs. Reasons for restricted recommendation were 70%, 39%, and 60%, 
and for not recommended were 100%, 57% and 21% respectively. Within each deci-
sion parameter the most common reason for restricting the market authorization 
indication was related to the drug not being cost-effective (57%). The most common 
reason for not recommending a drug was lack of long term data on efﬁcacy (86%). 
CONCLUSIONS: Despite that large variations in results between agencies were 
observed, data demonstrating efﬁcacy of the drug appeared to be the most important 
factor in getting a recommendation for type 2 diabetes treatment. A high incremental 
cost-effectiveness ratio was likely to lead to restrictions in indication (NICE, SMC and 
TLV) whereas lack of long term data could lead to the drug not being recommended 
(IQWIG and CVZ).
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OBJECTIVES: There is increasing focus on the ethical analysis in Health Technology 
Assessments (HTA). Due to the escalating epidemic of diabetes, diabetes has become 
an urgent health concern. We therefore systematically reviewed published articles 
describing the ethical aspects of pharmacological treatment and self management 
of diabetes. METHODS: PubMed was searched from inception to 2009 using the 
following combinations of keywords: ethics AND diabetes NOT screening NOT 
transplant. Articles were initially screened for relevance by reading title and abstract. 
If deemed appropriate, by two independent reviewers, full copies of the remaining 
articles were retrieved for further review. RESULTS: Out of 336 articles, only six 
studies were deemed appropriate. The main reason for this high level of rejected arti-
cles was that the majority of identiﬁed articles commented on the ethical approval in 
connection to conducting clinical studies rather than on the ethical aspects of imple-
menting and using the speciﬁc technology. One study described the ethical concern 
related to the costly late complications of diabetes compared to preventing late com-
plications by prescribing and reimbursing insulin. Other ethical issues concerned 
self management and the transferral of responsibility from physician to patient and 
the patient’s capabilities for self management. For people with impaired glucose toler-
ance there were also ethical issues related to initiating a preventive pharmacological 
treatment of the “otherwise well”. Lastly, there is an ethical issue between the norma-
tive gold standard for a healthy and moral lifestyle and a culture of self that values 
authenticity and originality. CONCLUSIONS: Due to the escalating prevalence 
of diabetes and emphasis on ethical analysis in HTAs, both payers and the industry 
needs to get a better understanding of the ethical aspects of self management and 
pharmacological treatment of diabetes. More research should be allocated towards 
investigating the ethical aspects of self management and pharmacological treatment 
of diabetes.
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APPLICATION OF HTA TO ANTIDIABETIC DRUG FORMULARY 
DECISIONS
Andreykiv M, Wiebinga C
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OBJECTIVES: To compare Health Technology Assessments (HTAs) and reimburse-
ment decisions of a novel antidiabetic drug class, by health care agencies worldwide. 
METHODS: We conducted manual searches of 54 health care agencies’ web sites 
from January 2008 to May 2009. HTAs regarding diabetes were collected and each 
was assessed for date, type (e.g., single drug versus class review) and scope (e.g., 
medicine name). Using a standardized set of categorical criteria, we investigated rec-
ommendations, as well as presence of supporting evidence (e.g., reported outcome 
measures, information sources, and key decision drivers). RESULTS: A total of 21 
completed diabetes assessments were assessed. Data were retrieved from 9 agencies in 
9 countries. The agencies published 21 assessments on diabetes during the review 
period; including 4 clinical guidelines, 9 single drug appraisals and 8 class reviews. Of 
